Cargando…

Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users

Objective. To compare the oral abuse potential of hydrocodone extended-release (ER) tablet developed with CIMA(®) Abuse-Deterrence Technology with that of hydrocodone immediate release (IR). Design. Randomized, double-blind, placebo-controlled, crossover study. Setting and Patients. One study site i...

Descripción completa

Detalles Bibliográficos
Autores principales: Darwish, Mona, Bond, Mary, Ma, Yuju, Tracewell, William, Robertson, Philmore, Webster, Lynn R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5283701/
https://www.ncbi.nlm.nih.gov/pubmed/27330154
http://dx.doi.org/10.1093/pm/pnw122
_version_ 1782503536276275200
author Darwish, Mona
Bond, Mary
Ma, Yuju
Tracewell, William
Robertson, Philmore
Webster, Lynn R.
author_facet Darwish, Mona
Bond, Mary
Ma, Yuju
Tracewell, William
Robertson, Philmore
Webster, Lynn R.
author_sort Darwish, Mona
collection PubMed
description Objective. To compare the oral abuse potential of hydrocodone extended-release (ER) tablet developed with CIMA(®) Abuse-Deterrence Technology with that of hydrocodone immediate release (IR). Design. Randomized, double-blind, placebo-controlled, crossover study. Setting and Patients. One study site in the United States; adult nondependent, recreational opioid users. Methods. After confirming their ability to tolerate and discriminate hydrocodone IR 45 mg from placebo, eligible participants were randomized to receive each of the following oral treatments once: finely crushed placebo, hydrocodone IR 45-mg powder, intact hydrocodone ER 45-mg tablet, and finely crushed hydrocodone ER 45-mg tablet. Primary pharmacodynamic measure was “at the moment” drug liking. Secondary measures included overall drug liking, drug effects (e.g., balance, positive, negative, sedative), pupillometry, pharmacokinetics, and safety. Results. Mean maximum effect (E(max)) for “at the moment” drug liking was significantly lower for intact (53.9) and finely crushed hydrocodone ER (66.9) vs. hydrocodone IR (85.2; P < 0.001). Drug liking for intact hydrocodone ER was comparable to placebo (E(max): 53.9 vs. 53.2). Secondary measures were consistent with these results, indicating that positive, negative, and sedative drug effects were diminished with intact and crushed hydrocodone ER tablet vs. hydrocodone IR. The 72-hour plasma concentration-time profile for each treatment mimicked its respective “at the moment” drug-liking-over-time profile. Incidence of adverse events was lower with intact hydrocodone ER (53%) vs. hydrocodone IR (79%) and finely crushed hydrocodone ER (73%). Conclusions. The oral abuse potential of hydrocodone ER (intact and finely crushed) was significantly lower than hydrocodone IR in healthy, nondependent, recreational opioid users. Hydrocodone ER was generally well tolerated.
format Online
Article
Text
id pubmed-5283701
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-52837012017-02-08 Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users Darwish, Mona Bond, Mary Ma, Yuju Tracewell, William Robertson, Philmore Webster, Lynn R. Pain Med OPIOIDS, SUBSTANCE ABUSE & ADDICTIONS SECTION Objective. To compare the oral abuse potential of hydrocodone extended-release (ER) tablet developed with CIMA(®) Abuse-Deterrence Technology with that of hydrocodone immediate release (IR). Design. Randomized, double-blind, placebo-controlled, crossover study. Setting and Patients. One study site in the United States; adult nondependent, recreational opioid users. Methods. After confirming their ability to tolerate and discriminate hydrocodone IR 45 mg from placebo, eligible participants were randomized to receive each of the following oral treatments once: finely crushed placebo, hydrocodone IR 45-mg powder, intact hydrocodone ER 45-mg tablet, and finely crushed hydrocodone ER 45-mg tablet. Primary pharmacodynamic measure was “at the moment” drug liking. Secondary measures included overall drug liking, drug effects (e.g., balance, positive, negative, sedative), pupillometry, pharmacokinetics, and safety. Results. Mean maximum effect (E(max)) for “at the moment” drug liking was significantly lower for intact (53.9) and finely crushed hydrocodone ER (66.9) vs. hydrocodone IR (85.2; P < 0.001). Drug liking for intact hydrocodone ER was comparable to placebo (E(max): 53.9 vs. 53.2). Secondary measures were consistent with these results, indicating that positive, negative, and sedative drug effects were diminished with intact and crushed hydrocodone ER tablet vs. hydrocodone IR. The 72-hour plasma concentration-time profile for each treatment mimicked its respective “at the moment” drug-liking-over-time profile. Incidence of adverse events was lower with intact hydrocodone ER (53%) vs. hydrocodone IR (79%) and finely crushed hydrocodone ER (73%). Conclusions. The oral abuse potential of hydrocodone ER (intact and finely crushed) was significantly lower than hydrocodone IR in healthy, nondependent, recreational opioid users. Hydrocodone ER was generally well tolerated. Oxford University Press 2017-01 2017-01-30 /pmc/articles/PMC5283701/ /pubmed/27330154 http://dx.doi.org/10.1093/pm/pnw122 Text en © 2016 American Academy of Pain Medicine. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creative commons. org/licenses/by-nc-nd/4.0/ (http://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle OPIOIDS, SUBSTANCE ABUSE & ADDICTIONS SECTION
Darwish, Mona
Bond, Mary
Ma, Yuju
Tracewell, William
Robertson, Philmore
Webster, Lynn R.
Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
title Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
title_full Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
title_fullStr Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
title_full_unstemmed Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
title_short Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
title_sort abuse potential with oral route of administration of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in nondependent, recreational opioid users
topic OPIOIDS, SUBSTANCE ABUSE & ADDICTIONS SECTION
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5283701/
https://www.ncbi.nlm.nih.gov/pubmed/27330154
http://dx.doi.org/10.1093/pm/pnw122
work_keys_str_mv AT darwishmona abusepotentialwithoralrouteofadministrationofahydrocodoneextendedreleasetabletformulatedwithabusedeterrencetechnologyinnondependentrecreationalopioidusers
AT bondmary abusepotentialwithoralrouteofadministrationofahydrocodoneextendedreleasetabletformulatedwithabusedeterrencetechnologyinnondependentrecreationalopioidusers
AT mayuju abusepotentialwithoralrouteofadministrationofahydrocodoneextendedreleasetabletformulatedwithabusedeterrencetechnologyinnondependentrecreationalopioidusers
AT tracewellwilliam abusepotentialwithoralrouteofadministrationofahydrocodoneextendedreleasetabletformulatedwithabusedeterrencetechnologyinnondependentrecreationalopioidusers
AT robertsonphilmore abusepotentialwithoralrouteofadministrationofahydrocodoneextendedreleasetabletformulatedwithabusedeterrencetechnologyinnondependentrecreationalopioidusers
AT websterlynnr abusepotentialwithoralrouteofadministrationofahydrocodoneextendedreleasetabletformulatedwithabusedeterrencetechnologyinnondependentrecreationalopioidusers